Outcome of Board Meeting_Change in Long Term Incentive Plan
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board approved FY2026 audited financial results and recommended a final dividend of Rs. 0.50 per share (10% on Rs. 5 face value), payable by August 31, 2026 with record date July 3, 2026. The company will replace statutory auditors B S R & Co. LLP with S R Batliboi & Associates LLP for 5 years. Six new directors are being appointed including pharma veterans Rajiv Malik and Daniel Bradbury. Key transaction: Biocon will acquire the remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) by issuing 87.92 lakh equity shares at Rs. 376.16 per share (worth Rs. 330.73 crore), taking BBL ownership to ~99.99%. OCDs and CCDs held by Goldman Sachs and Edelweiss in BBL will also convert to equity shares, simplifying the corporate structure.
The BBL full integration through share swap consolidates Biocon's global biosimilars business and could unlock operational synergies. The preferential share issuance causes dilution but strengthens subsidiary control. The modest 10% dividend is in line with historical payouts and should provide stable income support.